These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36029150)

  • 21. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
    Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2017; 10():47-56. PubMed ID: 28255251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
    Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
    Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase.
    Cheng Y; Liu L; Xue Y; Zhou S; Li Y
    J Clin Pharm Ther; 2022 Aug; 47(8):1186-1193. PubMed ID: 35307850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on acalabrutinib to treat chronic lymphocytic leukemia.
    Blackmon A; O'Brien S
    Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.
    Surendran S; Paul D; Pokharkar S; Choulwar S; Deshpande A; Giri S; Satheeshkumar N
    J Pharm Biomed Anal; 2019 Feb; 164():509-513. PubMed ID: 30453157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
    Edlund H; Bellanti F; Liu H; Vishwanathan K; Tomkinson H; Ware J; Sharma S; Buil-Bruna N
    Br J Clin Pharmacol; 2022 Feb; 88(2):846-852. PubMed ID: 34265100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
    Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
    Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects.
    Lv Y; Luo BY; LaBadie RR; Zhu H; Feng Y; Ernst C; Crownover PH; Liang Y; Zhao Q
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):573-581. PubMed ID: 32463593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
    Moorthy G; Pouliot GP; Graham L; Pilling E; Jung L; Alcobi R; Zhu Y; Li Y; Sidhu S; Forte P; Mugundu G
    Br J Clin Pharmacol; 2023 Sep; 89(9):2775-2787. PubMed ID: 37055936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian.
    Kanefendt F; Brase C; Unger S; Kubitza D
    Clin Pharmacol Drug Dev; 2023 Feb; 12(2):219-230. PubMed ID: 36507617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
    Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
    J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
    Krishna G; Ma L; Martinho M; O'Mara E
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
    Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
    Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
    Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
    de Bruin TW; Reele S; Hamer-Maansson JE; Parikh S; Tang W
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):118-30. PubMed ID: 27138025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of acalabrutinib in patients with mantle cell lymphoma.
    Awan FT; Jurczak W
    Expert Rev Hematol; 2018 Jun; 11(6):495-502. PubMed ID: 29737219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water.
    Kim EY; Lee SY; Jeon JY; Im YJ; Kim Y; Kim HI; Shin KS; Park SJ; Seo YH; Lee JY; Park JK; Chae SW; Kim MG
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):437-45. PubMed ID: 24786013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers.
    Liu Y; Jia J; Liu G; Li S; Lu C; Liu Y; Yu C
    Clin Ther; 2009 Apr; 31(4):777-83. PubMed ID: 19446150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric-Coated Tablets in Healthy Subjects.
    Chen Z; Gan F; Rao X; Huang X; Chen H
    Clin Pharmacol Drug Dev; 2021 May; 10(5):502-509. PubMed ID: 33128847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.